Tegafur
- Generic Name
- Tegafur
- Brand Names
- Teysuno
- Drug Type
- Small Molecule
- Chemical Formula
- C8H9FN2O3
- CAS Number
- 17902-23-7
- Unique Ingredient Identifier
- 1548R74NSZ
- Background
Tegafur (INN, BAN, USAN) is a prodrug of Fluorouracil (5-FU), an antineoplastic agent used as the treatment of various cancers such as advanced gastric and colorectal cancers. It is a pyrimidine analogue used in combination therapies as an active chemotherapeutic agent in conjunction with Gimeracil and Oteracil, or along with Fluorouracil as Tegafur-uracil. ...
- Indication
Indicated for the treatment of cancer usually in combination with other biochemically modulating drugs.
Indicated in adults for the treatment of advanced gastric cancer when given in combination with Cisplatin .
Indicated for the first-line treatment of metastatic colorectal cancer with Uracil and calcium folinate .
- Associated Conditions
- Stage IV Gastric Cancer
- Associated Therapies
- -
The Efficacy and Safety of Benmelstobart for GC/EGC
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT06603974
The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction
- Conditions
- Interventions
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT06396585
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-04-25
- Target Recruit Count
- 120
- Registration Number
- NCT06383078
PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Target Recruit Count
- 45
- Registration Number
- NCT06354140
- Locations
- 🇨🇳
Army Medical Center of the People's Liberation Army, Chongqing, Chongqing, China
Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-04-01
- Target Recruit Count
- 32
- Registration Number
- NCT06339619
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Fujian Medical University
- Target Recruit Count
- 100
- Registration Number
- NCT05914610
Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Taizhou Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05817201
- Locations
- 🇨🇳
Haihua Yang, Taizhou, Zhejiang, China
🇨🇳Taizhou Enze Medical Center(Group) Enze Hospital, Taizhou, Zhejiang, China
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05223088
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, China
Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer
- First Posted Date
- 2020-01-03
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 300
- Registration Number
- NCT04216758
- Locations
- 🇨🇳
Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University; 270 Dong An Road, Shanghai 200032, China, Shanghai, China
Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 616
- Registration Number
- NCT04135781
- Locations
- 🇨🇳
Zhejiang Cancer Hospital；Cancer hospital of the university of chinese academy of sciences, Hangzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.